Product News

Found 260,911 articles

• Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology

  5/8/2023

  ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of its analytical validation study for the Avantect™ Pancreatic Cancer Test in Clinical Gastroenterology and Hepatology.

• Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

  5/8/2023

  Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

• New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

  5/8/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.

• Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

  5/8/2023

  Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

• Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

  5/8/2023

  Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, hosted a key opinion leader webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease.

• ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

  5/8/2023

  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD.

• NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

  5/8/2023

  Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.

• Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

  5/8/2023

  Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.

• Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions

  5/8/2023

  Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.

• Trevena Announces Approval of OLINVYK in China

  5/8/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.

• SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

  5/8/2023

  SciSparc Ltd. announced that its joint venture MitoCareX Bio, which focuses on the discovery and development of potential drugs for cancers, rare diseases and other life-threatening conditions, succeeded to develop its core algorithm for allowing the generation of reliable 3D comparative models of human SLC25A mitochondrial carrier proteins - promising transporting targets for innovating therapies.

• KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

  5/8/2023

  KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.

• Boudewijn van Lent Named President and CEO of VanDeMark Chemicals

  5/8/2023

  VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.

• Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

  5/8/2023

  Ascletis Pharma Inc. announces that the China National Medical Products Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.

• Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023

  5/8/2023

  Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of results from two clinical studies for adults with hepatorenal syndrome with rapid reduction in kidney function1 treated with TERLIVAZ® for injection at Digestive Disease Week® 2023, taking place in Chicago, Ill.

• Devyser's clinical laboratory receives CLIA certification

  5/8/2023

  Devyser is announcing that the company's clinical testing laboratory in Roswell in Atlanta, Georgia, has received CLIA certification.

• Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™

  5/8/2023

  Masimo announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.

• Dentsply Sirona to Participate in Upcoming Investor Conferences

  5/8/2023

  DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced its participation at upcoming conferences.

• Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

  5/8/2023

  Kintara Therapeutics, Inc. today announced that its President and CEO, Robert E. Hoffman , will present a corporate overview at the Sidoti Micro-Cap Virtual Conference being held on May 10 – 11, 2023.

• Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates

  5/8/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.